chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Sore arm at site of injection; This is a spontaneous report from a contactable healthcare professional. A 48-year-old male patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number EL3246), intramuscular (left arm) from 14Jan2021 15:00 to 14Jan2021 15:00 at a single dose for covid-19 immunization. Medical history included High Blood Pressure. Concomitant medication included losartan. The patient experienced sore arm at site of injection on 14Jan2021 21:00. No treatment was received for the event. The outcome of the event was not recovered.
my arm is swollen; tingling; COVID arm; arm is infected; redness is spreading; rash on front side of the arm, almost going to the under arm; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (my arm is swollen), PARAESTHESIA (tingling), VACCINATION COMPLICATION (COVID arm), LOCALISED INFECTION (arm is infected) and ERYTHEMA (redness is spreading) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 31-Jul-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PERIPHERAL SWELLING (my arm is swollen), PARAESTHESIA (tingling), VACCINATION COMPLICATION (COVID arm), LOCALISED INFECTION (arm is infected), ERYTHEMA (redness is spreading) and RASH (rash on front side of the arm, almost going to the under arm). At the time of the report, PERIPHERAL SWELLING (my arm is swollen), PARAESTHESIA (tingling), VACCINATION COMPLICATION (COVID arm), LOCALISED INFECTION (arm is infected), ERYTHEMA (redness is spreading) and RASH (rash on front side of the arm, almost going to the under arm) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant product reported by reporter.  No treatment medication reported by reporter.   Reporter did not allow further contact
patient received 2nd dose on 4/22/21; Patient under 18 years old that was given the first dose; This spontaneous case was reported by a nurse and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient under 18 years old that was given the first dose) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient received 2nd dose on 4/22/21) in a 17-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 014C21A and 040A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Mar-2021 at 4:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Apr-2021 at 4:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 24-Mar-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient under 18 years old that was given the first dose). On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient received 2nd dose on 4/22/21). At the time of the report, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Patient under 18 years old that was given the first dose) had resolved and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (patient received 2nd dose on 4/22/21) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medications were not reported.  Treatment information was not provided.    Most recent FOLLOW-UP information incorporated above includes: On 20-Jul-2021: Significant follow up- On 20 -JUL-2021 , Containing Patient received second dose also
Immediate anaphylaxis to "test dose".  On August 25, 1993 my nurse manager came to me and told me she had received a message from employee health and that my 2nd series of the HepB vaccine was way overdue and to go there immediately for my injection.  I could not believe it.  (And I was still having diarrhea and bowel incontinence and just all around sick from June vaccine).    I went to employee health and reminded the nurse that I was not taking further vaccines.  She told me,  again,  HepB vaccines do not have serious adverse effects.   I refused, and was sitting in a chair and she pulled my scrub sleeve up and proceded to clean my arm with an alcohol swab.  I stood up and said "I am not  taking it!"    She told me she would give me a  "very small" sub q  test dose on my shoulder to prove to me it was not the vaccines causing the problems.   Immediately there was a throbbing pain in my shoulder and I told her and she said  "You are having a reaction, there is a large wheal."  I then got dizzy,  I was wheezing and my airway was closing off. Hypertension 200/120, tachycardiac, trembling, diaphoretic. I was given IM Epinephrine and taken to ER.    In the ER I was given IM Benadryl and IM Decadron.  My health never returned to normal following these vaccines.  A long haul, a snowball of chronic health issues.
Received vaccine at 5:30 pm.  Around 45 min later, began with a "rash", hot feeling around neck.  "Fine lighter colored 'bumps'", no SOB, but itching/burning.  Took a shower & noted about 10 nickel-quarter sized hives from neck to umbilicus.  Took 100 mg Benadryl about 6:30 pm & 50 mg at midnight.  Woke up next morning without sequela ("I was fine.").
PAIN AT SITE OF INJECTION; SLEPT THROUGHOUT THE DAY; FATIGUE; FELT LIKE NEEDLE HIT THE BONE; CHILLS; FEVER; This spontaneous report received from a patient concerned a 67 year old female. The patient's weight was 109 pounds, and height was 61 inches. The patient's pre-existing medical conditions included the patient was not pregnant at the time of reporting. The patient received covid-19 vaccine  (suspension for injection, route of admin not reported, batch number: 205A201A, expiry: UNKNOWN) dose was not reported, administered on 22-MAY-2021 for prophylactic vaccination. No concomitant medications were reported. On 22-MAY-2021, the subject experienced felt like needle hit the bone. On 22-MAY-2021, the subject experienced chills. On 22-MAY-2021, the subject experienced fever. Laboratory data included: Body temperature (NR: not provided) 99 F. On 23-MAY-2021, the subject experienced slept throughout the day. On 23-MAY-2021, the subject experienced fatigue. On 24-MAY-2021, the subject experienced pain at site of injection. Laboratory data (dates unspecified) included: Body temperature (NR: not provided) 97 F. The action taken with covid-19 vaccine was not applicable. The patient recovered from chills, and fatigue on MAY-2021, pain at site of injection on 24-MAY-2021, and fever on 23-MAY-2021, and the outcome of felt like needle hit the bone and slept throughout the day was not reported. This report was non-serious.
body achiness; fever; This case was reported by a consumer via call center representative and described the occurrence of general body pain in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 22nd July 2020, the patient received the 2nd dose of Shingrix. On 23rd July 2020, 1 days after receiving Shingrix, the patient experienced general body pain and fever. On an unknown date, the outcome of the general body pain and fever were not recovered/not resolved.   It was unknown if the reporter considered the general body pain and fever to be related to Shingrix.  Additional case details were reported as follows: The age at vaccination was not reported. The patient had fever of 101 degree F with body achiness.  No additional information were provided. The reporter did not consent to follow up. This case has been linked with case US2020140195, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020140195:same reporter
Zostavax given on 4/11/07 woke up 4/12/07 arm with dizziness, disequilibrium and mild vertigo
Delayed injection site reaction. Day 8 noticed itching and redness at injection site which has continued on day 9.  Days 1-4 noticed a small area of lower lip tingling with pressure or tooth brushing. Resolved day 5.
About 14 hours after the vaccine was given pt woke up with itchy rash. It bothered him enough that he couldn't sleep. Seen in office next morning. On PE had no fever and no other symptoms besides rash. Rash : morbilliform, symmetrical, chest, trunk, back, faintly on arms, slight on neck. Spares palms and soles and lower legs. no mucosal changes: eyes, throat normal.
Chest Pain, pressure, havyness, dizziness. Ended up going to ER. Tests indicate pericarditis. Currently treated with anti inflatory drugs.  It has gotten bit better, but not yet cured.
pt c/o difficulty swallowing and a scratchy throat within 20 min of receiving vaccine.  Patient given 25mg Benadryl and monitored for 30 min.   vital signs stable.  25 min later, no further symptoms and patient was released to home
Fever, screaming, lethargic, and loss of eye contact.  4/11/08 Reviewed PCP medical records which included vax records & peds neurologist evaluation. FINAL DX: PDD, autism spectrum disorder (high functioning) Records reveal patient initially dx w/PDD 6/1997 & autism 3/2000.  Lack of speech dx 4/1996.  ADHD, aggressive, impulsive.  Tx w/meds/ST/OT/early childhood intervention & secretin infusions.  Neurologist records reveal patient experienced tantrums, frustration & low mood.  Noted parental concerns began s/p initial MMR of 04/1995.  Continued special education class w/1-1 aide & medication was recommended.
FUNGAL INFECTION IN THE FACE; PERSISTENT PAIN IN THE LEFT SHOULDER; This spontaneous report received from a patient concerned a male of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine  (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on MAY-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported.  On 03-SEP-2021, the patient experienced fungal infection in the face. On 03-SEP-2021, the patient experienced persistent pain in the left shoulder. The action taken with covid-19 vaccine was not applicable. The patient had not recovered from persistent pain in the left shoulder, and the outcome of fungal infection in the face was not reported.  This report was non-serious.
SWELLING, TENDER TO TOUCH, REDDISH PURPLE COLOR, PAIN WITH MOVEMENT
This spontaneous report as received from a healthcare worker refers to a patient of unknown age and gender. On 06-JUL-2015 the patient was vaccinated with oral, ROTATEQ (dose was not reported, route of vaccination defaulted to oral, lot # K016314 with expiration date: 05-JUN-2016) which was improperly stored. This is one of several reports from the same reporter. Additional information has been requested.
Patient moved her right hand to the left arm with needle in arm 1 and 1/2 " and her finger touched needle while inserting in arm. Needle not all the way to point to give vaccine. So the needle was withdrawn without shot given in left arm. The needle was covered by safety device and place in sharps container wasting the vaccine. So after drawing up a new shot for the right arm, the customer was ok giving in right arm. She was ok with left arm when left store.
Death Narrative: Around the end of January 2021, patient was admitted to a home hospice program due to worsening of patient's Parkinson's Disease and Dementia. It was noted on the hospice programs Plan of Care that patient had severe, progressive dysphagia due to disease. Patient lost 20 pounds over the last 2 months prior to admission to hospice program. Patient had severe tremors, dystonia, and was dyspneic with minimal exertion. Patient received Moderna's Covid vaccine on 3/3/21. On 3/13/21, patient got progressively worse. He stopped eating and drinking and started to exhibit Cheyne-Stokes breathing. Hospice nurse noted that patient only had a few days remaining. On 3/18/21, patient passed away.
This spontaneous report refers to a 60 year old female patient. On 03-DEC-2013 reported as about one week ago, the patient was vaccinated with ZOSTAVAX. Dose, lot and expiry date were not reported. Concomitant medications included blood pressure medication and a statin. On 10-DEC-2013, 8 days after onset of therapy the patient experienced a rash on the right side of her head and burning at the site of the rash after receiving ZOSTAVAX, six inches by three inches in diameter (shingles). The outcome event is unknown. Anti-viral medication was prescribed as treatment for event. She has not visited her Nurse Practitioner yet but agreed to receive the packet to her. No PQC was reported. No additional AE information was provided. The patient had seen a physician at the healthcare facility where I work. No lab study was performed. Additional information has been requested.
Migraines, body aches, severely sore Lt arm, extremely fatigued, nausea, and congestion
1429-12 mins after injection i got tachycardic, hyptertensive, flushed, itchy throat, feeling of cough/tickle in throat, sensation of a pill stuck in throat, cold sweats. 185/105 bp 124 oxygen stayed fine the whole time.  50mg benadryl po 1634 Symptoms didn't subside. Tachy and bp got a little better  Solumedrol injection at around 1800 at the immediate care
Having swelling at the injection site; Major itch at the injection site; This is a spontaneous report from a contactable consumer, the patient. A 49-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the right arm on 20Apr2021 at 21:15 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant past medical history. The patient had no known allergies to medications, food or other products. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the right arm on 09Mar2021 at 02:15 (at the age of 49-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021 at 06:30, the patient had swelling at the injection site and major itch. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events having swelling at the injection site and major itch at the injection site were unknown at the time of this report.   No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
7 days after vaccine patient had headache, tired, 21 days after vaccine-still tired, swollen glands, labs showed increased WBC-neg for EBS, On day 39-Swollen knees. Blood test for Anti-Streptolycin-O and CRP  1197/8.1 respectively.
Client was vaccinated with Moderna vaccines on 3/31 and 4/28/2021 for Covid.  Symptoms started 8/30: nasal congestion and headache.  Tested PCR + for Covid on 9/1 and 9/3/2021.  Reported as a case of breakthrough Covid illness in a fully vaccinated person.
wife received the second Shingrix dose one month after receiving the first / dose; This case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too short in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concomitant products included Herpes zoster (Shingrix).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix and an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too short. On an unknown date, the outcome of the drug dose administration interval too short was unknown.  Additional details were provided as follows: The patient's husband reported the case. The age at vaccination was not reported. The patient received the second Shingrix dose one month after receiving the first Shingrix dose, which led to shortening of vaccination schedule. No other information was reported by the reporter.  The reporter was unable to obtain date of birth with initials of the patient's wife, and the route of administration as well as the lot number/expiration date of the Shingrix doses received as the patient chose to end the call before any further questions could be asked. The reporter did not consent to follow-up.
This spontaneous report was received from a registered nurse referring to a 51 year old female patient with diabetes and hypertension. The patient's medical history included renal transplant and therapy with BETADINE for which she had developed an unspecified drug reaction or allergy. Concomitant therapies included aspirin (manufacturer unknown), LIPITOR, COREG, NOVOLOG, ZOFRAN and PROGRAF. On 17-OCT-2017, the patient was vaccinated with PNEUMOVAX 23 lot number N022703 (expiration date: 27-FEB-2019), intramuscularly in the deltoid, for prophylaxis (strength, dose or units were not reported). At the same time she was also vaccinated with FLUZONE (strength, indication, route, dose, units or lot number were not reported) at the same site in the deltoid area of the same unspecified arm. On 20-OCT-2017, 4 days after onset of therapy the patient experienced "cellulitis like symptom" from the area below the injection site down to the elbow. The outcome of "cellulitis like symptom" was unknown. The relatedness between the event and the suspect therapies was not provided. The patient sought medical attention and received treatment for the adverse event. No laboratory diagnostics or studies were performed. Upon internal review, cellulitis was determined to be medically significant. The reporter considered the event as serious because significant disability or incapacity, due to the patient did not want to move the arm.
51 yo male s/p full Pfizer vaccination: dose one on 3/1/2021 and dose two on 3/22/2021. Pt received first kidney transplant in 1994, which failed in 2007. He subsequently received a second kidney transplant in 2007. He is immunosuppressed on Gengraf, mycophenolate mofetil, and prednisone. Pt reports new onset of fever, cough, headache, and congestion/runny nose on 8/4. He denies any known exposure to COVID-19. COVID PCR results back positive on 8/4.
Pharmacist reports that 4-5 hours after the vaccine she had tightness of her chest.  She does take Ventolin which she took.  She reported it was different than her usual tightness of her chest that she gets.   She reports she was OK after that.
J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 11/3/2022 ASEPTIC NECROSIS OF BILAT HIPS
Itching, change in blood, spiked bpm, vision blurry, metal taste, pain in tongue as well as lips, insomnia, hyperactivity, pain in bones, pain in fingers and toes, weight loss, diarrhea, headache, dizziness, pain in arm
her b-cells are 1% of normal now; increase in hemolysis; This is a spontaneous report from a contactable consumer (patient's parent). A 15-year-old female patient (not pregnant) received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EW0185) via an unspecified route of administration on 16May2021 (15-year-old at time of vaccination), at single dose, for COVID-19 immunization. The patient's medical history included autoimmune hemolytic anemia. Concomitant medications were not reported. The patient previously received Rituximab in 2018 to ablate her B cells (for autoimmune hemolytic anemia). The patient experienced an increase in hemolysis for a period of 3 weeks after the shot, from 19May2021. The event resulted in Doctor or other healthcare professional office/clinic visit. Patient's parent reported, "My 15-year-old daughter has autoimmune hemolytic anemia. She received Rituximab that ablated her B cells in 2018. She experienced an increase in hemolysis. Hospital test showed that she did not develop any antibody. Please advise how we can check if she has any protection against COVID-19...Should she try to get the 2nd shot. Her hematologist is unsure if there will be any benefits." Her b-cells are 1% of normal now. The patient had no COVID-19 prior vaccination. COVID-19 was not tested post vaccination (as reported). No therapeutic measures were taken as a result of the events. The outcome of the event increase in hemolysis was recovered; outcome of other event was unknown.
fever between 99 and 102; This is a spontaneous report from a Pfizer sponsored program. A contactable consumer (patient) reporting for self. A patient of unspecified age and gender received BNT162B2 (BNT162B2, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on an unspecified date as DOSE 1, SINGLE for covid-19 immunisation. The patient medical history and concomitant medications were not reported. It was reported that patient had a fever between 99 and 102 for the whole three weeks since first vaccine on an unknown date. The patient underwent lab tests and procedures which included body temperature: between 99 and 102 (units unspecified) on an unknown date. The outcome of the event was unknown.  No follow-up attempts are possible. Information about lot/batch number cannot be obtained.
had covid end of sept. Got injection thurs.  Had headache thurs even. Sat said his face was numb like he had a dental proceedure and his right eye was not blinking . then had pain radiating down his right neck. Went to  Hospital.  Diagnosed as bells palsy.  Unable to go to work as of now. Reporting because not sure if it is the vaccine or what.
Patient experienced a panic attack, anxiety, sweating, nausea, increase heart rate and blood pressure
Four days after my initial injection I began to itch all over my body. This began about 30 minutes after I drank a cup of liquid yogurt. I did not have hives.  This lasted about three hours. Three days later I started to experience the same thing about half an hour after eating a piece of baked chicken and half of an orange. The itching was more severe. I call my pcp and she told me to take Zyrtec and Benadryl. I have been taking both since Friday February  5. The itching continues it gets better at times, not as severe and not all over my body, but it has not subsided completely during that time.
Information has been received from a registered nurse concerning a female (age not reported) with on known allergies or adverse drug reactions reported. On 9/27/06, the pt was vaccinated IM in the left deltoid with 1 ml (2 vials) of HPV vaccine (lot 0B37F). Concomitant therapy included a tetanus toxoid shot in the other arm. Subsequently, the pt experienced arm hurting. The registered nurse confirmed that the pain was at the injection site. The pt has not mentioned any other symptoms. The pt sought unspecified medical attention. The intervention to prevent serious criteria was 800 mg, of Motrin. The registered nurse reported that she did not know if the event would have worsened or improved without the intervention of Motrin. On 9/28/06, the pt returned to the physicians office and was fine, however her arm still hurt. At the time of this report, the pt had not recovered from the event. The reporter considered the event to be serious as an other important medical event (OMIC). Additional information has been requested.